Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 3;5:106. doi: 10.1038/s42003-022-03041-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Viral attachment 1 h post infection (hpi) measured by qPCR for viral Hexon over time following carvedilol (10 μM) treatment in OVCAR4 (n = 4 biological repeats) and Ov4carbo (n = 5 biological repeats) cells (ns P > 0.05). b Flow cytometry analysis of viral infectivity. Percentages of GFP positive OVCAR4 and Ov4Carbo cell populations measured 24 h after treatment with AD5-GFP (MOI 10) and carvedilol (10 μM) (n = 2 biological repeats; 10,000 events; ns P > 0.05). c) Representative western blot images of viral protein expression in Ov4Carbo cells following treatment with dl922-947 (MOI 1) and carvedilol (10 μM) 96-144 hpi. d, e Densitometry analysis of viral protein expression, expressed as ratios of d E1A/Hsc70 and e adenovirus structural proteins (Hexon + Penton + Fibre + core)/GAPDH (n = 5 biological repeats; mean ± SEM; paired t-test, *P ≤ 0.05). f Viral replication in Ov4Carbo cells following treatment with dl922-947 (MOI 1) and carvedilol (10 μM) 96-144 hpi as measured by qPCR for adenoviral Hexon (n = 6 biological repeats; mean ± SEM; paired t-test, *P ≤ 0.05). g, h Viral titre in Ov4Carbo cells following treatment with dl922-947 (MOI 1) and carvedilol (10 μM) 120 hpi (g) and 144 hpi (h), measured by TCid₅₀ (120 hpi: n = 4; 144 hpi: n = 3 biological repeats, geo mean ± 95% CI; data displayed as technical triplicates from each individual biological repeat assay).